{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-003020","form_type":"8-K","ticker":null,"cik":"0000786947","company_name":"ACURA PHARMACEUTICALS, INC","filed_at":"2024-01-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:26.915584+00:00","generated_at":"2026-06-07T01:08:58.840856+00:00","sec_items":["1.01","2.01","2.03","9.01"],"event_type":"debt","sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Acura gets $250K loan from AD Pharma; warns of possible bankruptcy by Feb 2024","bullets":["Received $250K loan from Abuse Deterrent Pharma (AD Pharma) on Jan 8, 2024; total debt under November 2022 note now $4,919,279, interest 5.25%, due March 31, 2024.","Funds will support operations only through mid-Feb 2024; company states it may need to scale back or terminate operations or seek bankruptcy if no additional financing by end of Feb 2024.","AD Pharma, which owns ~65% of Acura's outstanding common stock, is controlled by Mr. Schutte, who directly owns ~13%.","Events of default include bankruptcy, failure to pay, and if Acura admits inability to pay debts; overdue amounts accrue at 7.5% per annum."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-003020","json":"https://secwatch.observer/filing/0001104659-24-003020.json","markdown":"https://secwatch.observer/filing/0001104659-24-003020.md","text":"https://secwatch.observer/filing/0001104659-24-003020.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/786947/000110465924003020/0001104659-24-003020-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/786947/000110465924003020/tm243090d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T01:08:58.840856+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9a985aa811c76ce9748e51aaf6733d7f9d356510","claim":"ACURA PHARMACEUTICALS, INC incurred loan of $250,000 with Abuse Deterrant Pharma, LLC at 5.25% maturing March 31, 2024.","evidence_excerpt":"we received a $250,000 loan from Abuse Deterrent Pharma, LLC (“AD Pharma”). This loan combined with previous loans","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/786947/000110465924003020/0001104659-24-003020-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"loan"},{"label":"Principal","value":"$250,000"},{"label":"Counterparty","value":"Abuse Deterrant Pharma, LLC"},{"label":"Rate","value":"5.25%"},{"label":"Maturity","value":"March 31, 2024"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}